Explore Jobs
Find Specific Jobs
Explore Careers
Explore Professions
Best Companies
Explore Companies
PacBio's peak revenue was $130.5M in 2021. The peak quarterly revenue was $55.7M in 2023(q3).
PacBio's revenue increased from $135.0k in 2009 to $128.3M currently. That's a 94,940.0% change in annual revenue.
Fiscal Year / Year | PacBio Revenue |
---|---|
2009 | $135,000 |
2010 | $1.7M |
2011 | $33.9M |
2012 | $26.0M |
2013 | $28.2M |
2014 | $60.6M |
2015 | $92.8M |
2016 | $90.7M |
2017 | $93.5M |
2018 | $78.6M |
2019 | $90.9M |
2020 | $78.9M |
2021 | $130.5M |
2022 | $128.3M |
Rate PacBio's financial transparency
PacBio saw the greatest revenue growth in 2011, when revenue increased by 1,922.88%.
PacBio had the lowest revenue growth in 2012, when revenue changed by -23.27%.
Year | PacBio Growth |
---|---|
2010 | 1140%↑ |
2011 | 1923%↑ |
2012 | -23%↓ |
2013 | 8%↑ |
2014 | 115%↑ |
2015 | 53%↑ |
2016 | -2%↓ |
2017 | 3%↑ |
2018 | -16%↓ |
2019 | 16%↑ |
2020 | -13%↓ |
2021 | 65%↑ |
2022 | -2%↓ |
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2010 | - | - | $220,000 | $280,000 |
2011 | $270,000 | $10.6M | $10.5M | $12.4M |
2012 | $10.0M | $7.3M | $2.8M | $5.9M |
2013 | $5.6M | $6.0M | $7.4M | $9.1M |
2014 | $11.6M | $11.4M | $20.6M | $16.9M |
2015 | $17.6M | $24.9M | $13.9M | $36.3M |
2016 | $19.1M | $20.7M | $25.1M | $25.7M |
2017 | $24.9M | $20.1M | $23.5M | $24.9M |
2018 | $19.4M | $21.6M | $18.2M | $19.5M |
2019 | $16.4M | $24.6M | $21.9M | $27.9M |
2020 | $15.6M | $17.1M | $19.1M | $27.1M |
2021 | $29.0M | $30.6M | $34.9M | $36.0M |
2022 | $33.2M | $35.5M | $32.3M | $27.4M |
2023 | $38.9M | $47.6M | $55.7M | - |
Do you work at PacBio?
Did PacBio meet its revenue projections?
CEO | Christian O. Henry |
Industry | Pharmaceuticals, Biotechnology & Life Sciences |
Company Type | Public |
Employees Number | 400 |
Date Founded | 2004 |
Headquarters | Menlo Park, California |
Number of Locations | 2 |
Revenue | $128.3M |
Net Income | -$314,248,000 |
Gross Proft | $49.0M (2022) |
PE Ratio | -3.25 |
Tax Rate | 0.3% |
Market Capitalization | $1.0B |
Total Assets | $1,767,086,000 |
Ticker | PACB |
PacBio received early financing of $4.5M on 2004-07-28.
Series | Round Size | Date |
---|---|---|
Series B | $4.5M | 07/2004 |
Series C | $7.7M | 08/2005 |
Series D | $50M | 01/2007 |
Series E | $100M | 07/2008 |
Series E | $68M | 10/2009 |
Series F | $109M | 07/2010 |
Post Ipo Debt | $20.5M | 02/2013 |
Post Ipo Debt | $900M | 02/2021 |
Investors | Security Type |
---|---|
Big Red Ventures | Series B |
Mohr Davidow Ventures | Series C |
ALLOY VENTURES | Series C |
Kleiner Perkins | Series C |
Mohr Davidow Ventures | Series D |
ALLOY VENTURES | Series D |
Kleiner Perkins | Series D |
Maverick Ventures | Series D |
Mohr Davidow Ventures | Series E |
Redmile Group | Series E |
Intel Capital | Series E |
ALLOY VENTURES | Series E |
DAG Ventures | Series E |
ALLIANCEBERNSTEIN L.P. | Series E |
Kleiner Perkins | Series E |
T. Rowe Price Group, Inc. | Series E |
Deerfield Capital Management | Series E |
Maverick Ventures | Series E |
Morgan Stanley | Series E |
Sutter Hill Ventures | Series E |
Wellcome Trust | Series E |
Intel Capital | Series E |
MONSANTO CO NEW | Series E |
Deerfield | Series E |
ALLIANCEBERNSTEIN L.P. | Series E |
Mohr Davidow Ventures | Series E |
Ontario Teachers Pension Plan | Series E |
ALLOY VENTURES | Series E |
DAG Ventures | Series E |
Kleiner Perkins | Series E |
T. Rowe Price Group, Inc. | Series E |
Maverick Ventures | Series E |
Morgan Stanley | Series E |
Mohr Davidow Ventures | Series F |
Sutter Hill Ventures | Series F |
Intel Capital | Series F |
ALLOY VENTURES | Series F |
DAG Ventures | Series F |
Deerfield | Series F |
GEN PROBE INC | Series F |
ALLIANCEBERNSTEIN L.P. | Series F |
Kleiner Perkins | Series F |
Maverick Ventures | Series F |
Morgan Stanley | Series F |
Deerfield | Post Ipo Debt |
SoftBank Group Corp | Post Ipo Debt |
Company Name | Average Salary | Revenue | Employee Size | Job Openings |
---|---|---|---|---|
Celera | $75,834 | - | 750 | - |
Vertex Pharmaceuticals | $95,952 | $8.9B | 3,400 | 286 |
Caliper Life Sciences | $81,030 | $109.8M | 200 | - |
Quidel | $71,489 | $1.7B | 1,500 | 8 |
Intellia Therapeutics | $79,975 | $52.1M | 211 | 44 |
BioReliance | $74,348 | $49.9M | 700 | - |
Alnylam Pharmaceuticals | $81,014 | $1.0B | 1,323 | 65 |
Illumina | $94,044 | $4.6B | 7,800 | 76 |
Geron | $56,851 | $596,000 | 15 | - |
OpGen | $47,663 | $2.6M | 48 | 1 |
Zippia gives an in-depth look into the details of PacBio, including salaries, political affiliations, employee data, and more, in order to inform job seekers about PacBio. The employee data is based on information from people who have self-reported their past or current employments at PacBio. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by PacBio. The data presented on this page does not represent the view of PacBio and its employees or that of Zippia.
PacBio may also be known as or be related to PACIFIC BIOSCIENCES OF CALIFORNIA, INC., PacBio, Pacific Biosciences, Pacific Biosciences of California Inc, Pacific Biosciences of California Inc. and Pacific Biosciences of California, Inc.